Piers Whitehead VaxGen, Vice President, Corporate and Business Development Piers Whitehead is currently Vice President of Corporate and Business Development at Vaxgen. In this position he has been deeply involved in the $877.5 millions Bioshield contract Vaxgen was awarded in November 2004 to supply 75 million doses of anthrax vaccine for civilian defense. He was formerly the vice president and head of Mercer Management Consulting’s San Francisco office. faccsf
